Cargando…
Anti-infective monoclonal antibodies: perils and promise of development
So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of...
Autores principales: | Reichert, Janice M., Dewitz, Matthew C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097328/ https://www.ncbi.nlm.nih.gov/pubmed/16518372 http://dx.doi.org/10.1038/nrd1987 |
Ejemplares similares
-
Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections
por: Reichert, Janice M.
Publicado: (2012) -
Moral outrage: Promise or peril?
por: Rushton, Cynda Hylton, et al.
Publicado: (2020) -
Monoclonal antibodies as anti-infective products: a promising future?
por: Pelfrene, E., et al.
Publicado: (2019) -
The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection
por: Rajaram, Sanjeeth, et al.
Publicado: (2020) -
The promises and perils of the neuroscience of creativity
por: Abraham, Anna
Publicado: (2013)